Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab versus ranibizumab for diabetic macular edema
NL-OMON47349Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of bevacizumab and ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Mean change in best corrected visual acuity from baseline to 6 months. Started Jun 2012; status: active, not recruiting.
02
Drugs
bevacizumabranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NL-OMON47349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47349.